User profiles for Emily Bethea
 | Emily D BetheaMassachusetts General Hospital Verified email at partners.org Cited by 958 |
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study
ED Bethea, K Gaj, JL Gustafson, A Axtell… - The lancet …, 2019 - thelancet.com
Background Low donor heart availability underscores the need to identify all potentially
transplantable organs. We sought to determine whether pre-emptive administration of …
transplantable organs. We sought to determine whether pre-emptive administration of …
[HTML][HTML] Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–40: a modelling study
Background Alcohol-related liver disease is the leading indication for liver transplantation in
the USA. After remaining stable for over three decades, the number of deaths due to alcohol-…
the USA. After remaining stable for over three decades, the number of deaths due to alcohol-…
Model to calculate harms and benefits of early vs delayed liver transplantation for patients with alcohol-associated hepatitis
Background & Aims Early liver transplantation (without requiring a minimum period of
sobriety) for severe alcohol-associated hepatitis (AH) is controversial: many centers delay …
sobriety) for severe alcohol-associated hepatitis (AH) is controversial: many centers delay …
Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs
An estimated 71 million people are infected with hepatitis C virus (HCV) globally, resulting
in about 400 000 deaths each year. 1 The availability of direct-acting antivirals (DAAs) offers …
in about 400 000 deaths each year. 1 The availability of direct-acting antivirals (DAAs) offers …
Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the …
A Al Jurdi, L Morena, M Cote, E Bethea… - American Journal of …, 2022 - Wiley Online Library
The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown
to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (…
to reduce the risk of SARS‐CoV‐2 infection in unvaccinated individuals during the Alpha (…
Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis
It is not standard practice to treat patients with acute hepatitis C virus (HCV) infection.
However, as the incidence of HCV in the United States continues to rise, it may be time to re‐…
However, as the incidence of HCV in the United States continues to rise, it may be time to re‐…
A prospective, multicenter study of the AIMS65 score compared with the Glasgow-Blatchford score in predicting upper gastrointestinal hemorrhage outcomes
MS Abougergi, JP Charpentier, E Bethea… - Journal of Clinical …, 2016 - journals.lww.com
Background: The AIMS65 score and the Glasgow-Blatchford risk score (GBRS) are validated
preendoscopic risk scores for upper gastrointestinal hemorrhage (UGIH). Goals: To …
preendoscopic risk scores for upper gastrointestinal hemorrhage (UGIH). Goals: To …
The impact of direct‐acting anti‐virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States
Background The hepatitis C virus (HCV) care cascade has changed dramatically following
the introduction of direct‐acting anti‐virals (DAAs). Up‐to‐date estimates of the cascade are …
the introduction of direct‐acting anti‐virals (DAAs). Up‐to‐date estimates of the cascade are …
Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication
Background & Aims Successful treatment of chronic hepatitis C with oral direct-acting
antivirals (DAAs) leads to virological cure, however, the subsequent risk of hepatocellular …
antivirals (DAAs) leads to virological cure, however, the subsequent risk of hepatocellular …
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
Objectives Oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have dramatically
changed the treatment paradigm. Our aim was to project temporal trends in HCV diagnosis, …
changed the treatment paradigm. Our aim was to project temporal trends in HCV diagnosis, …